Olivier Gremy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6285898/publications.pdf

Version: 2024-02-01

28	390	687220 13	752573 20
papers	citations	h-index	g-index

28	28	28	336
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Excretion of Pu-238 during Long-term Chelation Therapy by Repeated DTPA Inhalation. Health Physics, 2022, 123, 197-207.	0.3	3
2	Comparison of Local and Systemic DTPA Treatment Efficacy According to Actinide Physicochemical Properties Following Lung or Wound Contamination in the Rat. Frontiers in Pharmacology, 2021, 12, 635792.	1.6	6
3	Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake. Health Physics, 2021, 121, 494-505.	0.3	4
4	DTPA-Coated Liposomes as a New Delivery Vehicle for Plutonium Decorporation. Radiation Research, 2020, 195, 77-92.	0.7	1
5	From in vivo to in vitro models to assess bioavailability properties of Plutonium compounds. BIO Web of Conferences, 2019, 14, 02007.	0.1	1
6	Medical countermeasures against radionuclide contamination: An overview. BIO Web of Conferences, 2019, 14, 06001.	0.1	0
7	Modelling DTPA decorporation of Am in rats. BIO Web of Conferences, 2019, 14, 06003.	0.1	0
8	Chelation Treatment by Early Inhalation of Liquid Aerosol DTPA for Removing Plutonium after Rat Lung Contamination. Radiation Research, 2019, 192, 630.	0.7	14
9	Americium biodistribution in rats after wound contamination with different physicochemical forms in the presence or absence of plutonium: analyses using STATBIODIS. Journal of Radiological Protection, 2019, 39, 707-738.	0.6	2
10	Comments on â€œImproved Modeling of Plutonium-DTPA Decorporationâ€•(Radiat Res 2019; 191:201-10). Radiation Research, 2019, 192, 680.	0.7	4
11	Delivery of DTPA through Liposomes as a Good Strategy for Enhancing Plutonium Decorporation Regardless of Treatment Regimen. Radiation Research, 2018, 189, 477-489.	0.7	19
12	Decorporation Approach after Rat Lung Contamination with Plutonium: Evaluation of the Key Parameters Influencing the Efficacy of a Protracted Chelation Treatment. Radiation Research, 2017, 188, 632-641.	0.7	6
13	Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action. Radiation Research, 2016, 185, 568-579.	0.7	32
14	Medical countermeasures after a radiological event: An update from the CATO project. International Journal of Radiation Biology, 2014, 90, 1043-1047.	1.0	14
15	Decorporation Approach Following Rat Lung Contamination with a Moderately Soluble Compound of Plutonium Using Local and Systemic Ca-DTPA Combined Chelation. Radiation Research, 2012, 178, 217-223.	0.7	17
16	Plutonium Behavior after Pulmonary Administration According to Solubility Properties, and Consequences on Alveolar Macrophage Activation. Journal of Radiation Research, 2012, 53, 184-194.	0.8	22
17	MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy. Radiation Protection Dosimetry, 2011, 144, 371-375.	0.4	6
18	ISOTOPIC AND ELEMENTAL COMPOSITION OF PLUTONIUM/AMERICIUM OXIDES INFLUENCE PULMONARY AND EXTRA-PULMONARY DISTRIBUTION AFTER INHALATION IN RATS. Health Physics, 2010, 99, 380-387.	0.3	11

#	Article	IF	Citations
19	STRUCTURE OF A SINGLE MODEL TO DESCRIBE PLUTONIUM AND AMERICIUM DECORPORATION BY DTPA TREATMENTS. Health Physics, 2010, 99, 553-559.	0.3	24
20	Drosophila Translational Elongation Factor-1Î³ Is Modified in Response to DOA Kinase Activity and Is Essential for Cellular Viability. Genetics, 2010, 184, 141-154.	1.2	18
21	Preferential Decorporation of Americium by Pulmonary Administration of DTPA Dry Powder after Inhalation of Aged PuO₂Containing Americium in Rats. Radiation Research, 2010, 174, 637-644.	0.7	22
22	ModÃ©lisation de la dÃ©corporation du Pu/am par le dtpa. Radioprotection, 2009, 44, 431-446.	0.5	0
23	Simplified Structure of a New Model to Describe Urinary Excretion of Plutonium after Systemic, Liver or Pulmonary Contamination of Rats Associated with Ca-DTPA Treatments. Radiation Research, 2009, 171, 674-686.	0.7	19
24	In VitroandIn VivoAssessment of Plutonium Speciation and Decorporation in Blood and Target Retention Tissues after a Systemic Contamination followed by an Early Treatment with DTPA. Radiation Research, 2008, 170, 208-215.	0.7	16
25	Reduction of Peroxisome Proliferation-Activated Receptor Î³ Expression by Î³-Irradiation as a Mechanism Contributing to Inflammatory Response in Rat Colon: Modulation by the 5-Aminosalicylic Acid Agonist. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 911-920.	1.3	48
26	Activation of Alveolar Macrophages after Plutonium Oxide Inhalation in Rats: Involvement in the Early Inflammatory Response. Radiation Research, 2008, 170, 591-603.	0.7	12
27	Acute and persisting Th2-like immune response after fractionated colorectal Î³-irradiation. World Journal of Gastroenterology, 2008, 14, 7075.	1.4	41
28	Caffeic acid phenethyl ester modifies the Th1/Th2 balance in ileal mucosa after Î³-irradiation in the rat by modulating the cytokine pattern. World Journal of Gastroenterology, 2006, 12, 4996.	1.4	28